Sepsis
Conditions
Brief summary
In this project, intensive care unit (ICU) patients treated with beta-lactam antibiotics are included with the aim to investigate the potential underdosing in this patient group. Four regional ICU-clinics are recruiting consecutive patients (n=120) and samples are taken before the next dose is administered for three consecutive days.
Interventions
OTHERNo intervention.
Sponsors
Linkoeping University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Current treatment with beta-lactam antibiotics and admission to the ICU
Exclusion criteria
* Pregnancy, age below 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of patients below 16mg/L for piperacillin-tazobactam, 2 mg/L for meropenem and 4mg/L for cefotaxim | 3 days |
Secondary
| Measure | Time frame |
|---|---|
| Mortality in relation to initial levels of beta-lactam antibiotics as defined in primary outcome | 30 days |
| The rate of patients below 100% time over MIC in relation to the bacteria causing the infection. | 3 days |
| Kidney function measured as eGFR in relation to initial levels of beta-lactam antibiotics as defined in primary outcome | 3 days |
| SAPS-score in relation to initial levels of beta-lactam antibiotics as defined in primary outcome | 3 days |
| Days in intensive care unit in relation to initial levels of beta-lactam antibiotics as defined in primary outcome | 30 days |
Countries
Sweden
Outcome results
None listed